Journal of Clinical Oncology
Articles in this Issue
Regional disparities in prostate cancer mortality in the African Union: A retrospective analysis (1980-2023).
5053 Background: Prostate cancer represents a substantial health burden among men in Africa and is an important contributo...
Utilization of computed tomography scans and lung cancer development in patients with pulmonary symptoms: A national database study.
e13594 Background: Lung cancer screening with chest computed tomography (CT) is recommended for asymptomatic 50–80-year-ol...
Spatial characterization and predictive implications of the tumor immune microenvironment in stage III melanoma under neoadjuvant immunotherapy.
e21534 Background: Despite recent trials establishing neoadjuvant immune checkpoint blockade (ICB) as the standard of care...
Trends in lung adenocarcinoma incidence among younger adults in the United States: A SEER-based Joinpoint analysis.
e20113 Background: Patterns of lung adenocarcinoma (LUAD) incidence among younger adults remain underexplored, particularl...
A Ki-67/CD34 prognostic model for risk stratification in resected gastrointestinal stromal tumors.
e23515 Background: Accurate risk stratification is essential for guiding postoperative adjuvant therapy in resected gastro...
To re-test or not: Evaluating candidacy for precision therapy in breast cancer.
e12599 Background: Breast cancer is one of the most common types of cancer as well as a leading cause of cancer death amon...
Early mortality and contemporary survival in intravascular large B-cell lymphoma: A population-based SEER study.
e19089 Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive extranodal lymphoma that frequent...
EIF4B expression in lung squamous cell carcinoma using bulk and single-cell transcriptomic profiling.
e20537 Background: Dysregulated translation initiation is a hallmark of cancer progression and therapeutic resistance. Euk...
Reporting of patient-reported outcomes in randomized phase 3 clinical trials of FDA-approved medications in breast cancer.
e12693 Background: Patient-reported outcomes (PROs) capture symptoms, functional limitations, and quality of life directly...
Denosumab as an immune modulator: Results of a window-of-opportunity study in early breast cancer.
e12540 Background: Denosumab, a RANK ligand inhibitor, has been shown to improve disease free survival when given adjuvant...
Association patterns among patient-reported adverse events in advanced NSCLC: A post-hoc analysis of the CLIMEDIN randomized controlled trial.
e23271 Background: CLIMEDIN was a randomized controlled trial of digital support for patients with advanced or metastatic...
A phase II trial of ivonescimab for previously treated thymic carcinoma: UCLA L-11.
TPS8140 Background: Thymic carcinoma (TC) is a rare and aggressive thymic epithelial tumor (TET), accounting for approxima...
Organ-specific proteomic aging clocks (PACs) and mortality in cancer survivors.
12112 Background: Our study suggested that plasma conventional PACs can reflect, on average, accelerated aging in cancer s...
Off-target HLA matches for prediction of response in personalised cancer vaccines: A multi-trial retrospective analysis.
2653 Background: Personalized neoantigen vaccines aim to match epitopes to a patient's HLA genotype, yet many peptides bin...
Correlation between circulating tumor DNA and radiographic disease status in soft tissue sarcoma: A Mayo Clinic experience.
e23554 Background: Radiographic imaging remains the standard of care for disease surveillance and response assessment in s...
Early results of neoadjuvant therapy with pyrotinib, subcutaneous trastuzumab, and capecitabine for HER2-positive early breast cancer from a prospective, single-arm, multicenter trial.
606 Background: Neoadjuvant therapy has become a standard approach for HER2-positive early breast cancer, improving outcom...
Prognostic impact of latency interval on survival in second primary malignancies after head and neck cancer: A population-based SEER study.
e18098 Background: Survivors of head and neck cancer (HNC) are at increased risk of developing second primary malignancies...
Effect of hypofractionated radiotherapy plus GM-CSF on antitumor activity with PD-1/PD-L1 inhibitors in oligoprogressive advanced NSCLC: A prospective phase II study.
e20638 Background: Oligoprogressive disease during PD-1/PD-L1 therapy is a challenging acquired resistance pattern in adva...
Updated results of the randomized phase 2 dose optimization study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with advanced small cell lung cancer.
8109 Background: Alveltamig (ZG006) is a trispecific T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3,...
Temperature-controlled hand-foot cooling for prevention of chemotherapy-induced polyneuropathy (CIPN): Updated real-world data collection in 600 patients.
e24181 Background: Advancements in oncology have significantly improved overall survival rates for cancer patients, partic...
ErbB family members as mediators of acquired resistance to immunotherapy in high-grade serous ovarian cancer.
5548 Background: Efforts to improve immunotherapy for ovarian cancer (OC) have focused on optimizing T-cell effector-based...
Use of duration of response as an interpretable endpoint in non-small cell lung cancer drug approvals.
e23020 Background: Overall response rate (ORR) is used as an early endpoint indicative of efficacy in oncology clinical tr...
Kitchen radon exposure, ventilation behaviors, and awareness in non-smoking female lung adenocarcinoma patients.
e22554 Background: Radon is an established lung carcinogen, yet its exposure characteristics within household kitchen micr...
A common gene expression signature across multiple myeloma disease stages to identify high-risk of disease progression.
7560 Background: An accurate and timely identification of high-risk (HR) disease is crucial to maximize therapeutic opport...
Real-world utilization and outcomes of lenalidomide in MDS with low blasts and isolated deletion 5q (MDS w 5q).
11198 Background: Lenalidomide is the preferred first-line agent for lower risk MDS w 5q. It is associated with higher rat...